

## SUBJECT INDEX TO VOLUME 6

ABC transporters .....	435	targeting p70S6K by .....	83
in chemoresistance of glioma .....	439	targeting PI3K by .....	83
in glial cells .....	436	Apoptosis .....	135,188,472,681
Actin-binding proteins .....	249	caspase activation in .....	138
spatial organization of .....	249	imaging of .....	188
Actin filament .....	246	mechanism of SF-induced .....	138
as target for chemotherapy .....	251	natural bile acids as inducers of .....	682
isoforms of .....	246	reactive oxygen species (ROS) in .....	141
regulation of .....	246	BCR-ABL .....	645
role of myosin in regulation of .....	247	alternative inhibitors of .....	651
role of tropomyosin in regulation of .....	247	inhibition of .....	646
Adrenomedullin .....	635	signal transduction of .....	646
angiogenic control of .....	635	tyrosine kinase inhibition of .....	646
as prognostic indicator in tumor biology .....	636	Bisphosphonates .....	23
as tumor progression factor .....	635	in clinical trials .....	25
functions of .....	636	Breast cancer .....	39,365
gene structure of .....	635	anti-estrogen therapy for .....	467
in angiogenesis .....	637	aromatase inhibitors for .....	467
in breast cancer .....	637	ATP7B in .....	375
in endometrial tumors .....	638	biomarkers in .....	365
in ovarian cancer .....	639	breast cancer resistance protein in .....	374
in pancreatic cancer .....	638	cell-based screening assays for .....	462
in pheochromocytoma .....	639	chemotherapy for .....	366,456,468
in prostate cancer .....	638	co-expression of transport pumps in .....	375
in uterine leiomyoma .....	639	co-repressor mimics in .....	54
receptor/signal transduction of .....	635	cytochrome P <sub>450</sub> (CYP450) in .....	376
regulation of tumor/normal cell during		development of targeted therapeutics in .....	461
carcinogenesis by .....	639	drug resistance in .....	367
translation of .....	635	drug transport proteins in .....	367
Akt .....	78	enhancement of ER degradation as target in .....	56
in cell growth/survival .....	78	ER antagonists in .....	54
in metabolism .....	79	ER turnover rate in .....	39,52
inhibition of .....	81	glutathione-S-transferases in .....	375
AML1/RUNX1 .....	553	hormonal therapy for .....	366
dysfunction by point mutations .....	558	impact of ligands on intracellular shuttling in .....	39
in acute myeloid leukemia .....	556	influence of ligands on ER level in .....	52
in hematological disease .....	555	locally advanced/inflammatory/extreme risk in .....	459
point mutations of .....	556	locoregional treatment of .....	365
role in MDS/AML development .....	559	lung resistance protein in .....	374
structure/function of .....	555	mammalian target of rapamycin (mTOR) for .....	468
Angiogenesis .....	190,352	MDR1/P-glycoprotein in .....	368
molecular basis of .....	352	mechanisms of drug resistance in .....	375
Anti-cancer agent .....	17	metastatic based .....	459
anti-RAS directed compounds as .....	20	modifying ER shuttling/turnover rate in .....	53
bisphosphonates as .....	23	monoclonal antibodies for .....	366
dual FPTase-GGPTase-I inhibitors as .....	19	MRP1 in .....	373
farnesyltransferase inhibitors as .....	17	multiple drug resistance in .....	365
GGTIs as .....	20	non-invasive imaging of .....	476
histone deacetylase inhibitors as .....	25	pharmaceutical/clinical development of drug	
monoterpenes as .....	23	combinations for .....	473
Ras displacing compounds as .....	21	pharmacology of combination drug therapy for .....	464
statins as .....	22	regulation of ER concentration in .....	51
Anti-cancer therapy .....	15	regulation of ER mRNA expression in .....	51
targeting mevalonate pathway for .....	15	renal subcapsular models for .....	476
Anti-EGFR monoclonal antibodies .....	695	systemic therapy for .....	366
Antiestrogens .....	41	targeted agents for .....	460
Antisense oligonucleotides .....	81	targeted drug combinations for use in .....	455
targeting Akt by .....	83	therapies for .....	365,376
targeting cancer pathways with .....	81	topoisomerase II $\alpha$ in .....	375
targeting IRS proteins by .....	83		

transgenic models for .....	476	Cancer therapy .....	197,565
trastuzumab for .....	465	ionizing radiation in.....	197
treatment of.....	455	TGF beta inhibition for .....	565
Cancer.....	65,77,163,257,491,519,579,623,659,729	Carcinogenesis.....	613
Akt activation in .....	78	cysteinyl leukotriene receptors in.....	615
angiogenesis in .....	665	FLAP in.....	614
anti-invasive/anti-metastasis strategies in .....	729	5-HETE/5-oxoETEs in .....	616
ASO for treatment of.....	82	implications on.....	616
ATP-competitive inhibitors in .....	625	lipoxins/lipoxin A4 receptor in .....	616
cell dynamics control cell movement as target for....	738	5-lipoxygenase pathway of arachidonic acid	
chemokine targeted preclinical therapies in .....	665	metabolism in.....	613
combined strategy by Raf inhibitor/BAY 43-9006 in ..	630	5-Lox pathway in .....	614
cytokine-vaccine combination for.....	584	LTA4H/LTB4/LTB4 receptors in .....	615
cytoplasmic/non-receptor PTPs in.....	520	cDNA microarrays.....	711
DNA vaccination for .....	584	Cell cycle arrest .....	136
geldanamycin in.....	629	cell cycle events in.....	136
gene therapy for.....	585	DNA damage in.....	137
genetic amplification of hTERT in.....	163	mechanism of SF-induced.....	136
genetic amplification of hTR in.....	163	microtubule disruption in.....	137
GnRH-II in.....	263	role of cyclin dependent kinase inhibitors (CDKI) in	136
heat-shock protein 90 in.....	629	role of histone acetylation in.....	136
<i>HER-2</i> oncogene in.....	579	Cell-cycle regulation.....	349
<i>HER-2</i> specific tyrosine kinase inhibitors for .....	585	molecular basis of.....	349
herceptin in .....	583	Cell-matrix-contacts.....	93
hypothesis of hTERT repressor in.....	163	in metastatic cascade .....	93
immunological strategies for.....	584	Cell proliferation.....	181
immunotherapy for .....	491	activity of Na <sup>+</sup> /K <sup>+</sup> ATPase pump in .....	186
in post-genomic era.....	729	amino acid transport/metabolism in .....	184
inhibition of PI3K in .....	81	DNA synthesis in .....	185
inhibitors of mTOR in .....	81	lipid metabolism in .....	184
IRS proteins in .....	79	phosphate transport in .....	186
mechanisms of maintenance of telomeres in.....	163	Cetuximab.....	697
metabolism related pathways in.....	77	clinical results with.....	697
metastasis in.....	734	Chemokine .....	659
molecular basis for combination chemotherapy in....	579	angiogenesis in .....	665
monoclonal antibodies in .....	628	effect on tumor development.....	663
mTOR in.....	80	family of.....	659
non-ATP-competitive inhibitors in .....	626	in cancer .....	662
PI3-kinase in .....	66	in invasion .....	664
PI3K activation in .....	77	in proliferation.....	663
protein tyrosine phosphatases in.....	519	tumor associated macrophage infiltration in.....	665
PTEN in.....	80	Chemopreventive agent .....	711
rapamycin in.....	81	antioxidants as.....	718
Ras-Erk pathway in.....	67	fatty acid as.....	718
reactivation of telomerase in .....	163	in changing molecular blueprint of cancer.....	712
RTKs/small molecule inhibitors in.....	627	mining of markers/targets for.....	714
small molecule inhibitors in.....	625	mode of action of .....	711
Src family kinases in.....	67	non-steroidal anti-inflammatory drugs as.....	719
stem cell factor receptor/c-Kit as drug target in.....	65	phytochemicals as.....	719
synthetic carbohydrate antigens in.....	495	retinoids as.....	721
synthetic glycopeptides for.....	491	role for global gene expression pattern.....	711
target chemokine network for.....	659	selenium as .....	721
targeted therapies for .....	67,732	targets of.....	711
therapeutical application of GnRH analogs in.....	257	vitamins as.....	722
topo II-inhibitor combination chemotherapy in.....	593	Chemotherapy .....	588
treatment of.....	77	<i>HER-2</i> amplicon as target for.....	588
type II GnRH receptors in .....	263	Chronic myelogenous leukemia (CML).....	645
Cancer chemoprevention.....	613	molecularly targeted therapy for.....	645
5-lipoxygenase pathway of arachidonic acid		c-Kit.....	65
metabolism in.....	613	autocrine loops of.....	69
implications on.....	616	ectopic expression of.....	69
		gain-of-function mutations of.....	69

in signal transduction.....	66	$\gamma$ -H2AX.....	197
in tumors.....	69	after DNA damage by genetic/chemical intervention.....	202
Cisplatin.....	202	after IR in tumor cells.....	201
treatment with.....	202	as DNA damage response protein.....	198
Cisplatin-refractory patients.....	699	as dose-dependent surrogate for DNA damage.....	201
cetuximab monotherapy in.....	699	as marker of unrepaired DNA damage.....	201
combination of cetuximab with chemotherapy in.....	700	as therapeutic target for efficacy of radiation therapy.....	197
Conditional mouse tumor models.....	603	detected in irradiated human skin.....	202
switching-off oncogene expression in.....	604	deficient cells demonstrate radiation sensitivity of.....	201
Cytoskeleton.....	738	detected by phosphospecific antibodies.....	201
as target for therapies.....	738	in radiosensitive tumor cells.....	201
plasticity of.....	738	inhibition of.....	202
DNA damage.....	198	kinetics of.....	201
Drug resistance.....	347	persistence of.....	201
molecular basis of.....	347	Genomic profiling.....	711
Drug resistance.....	472	Glycans.....	738
EB1089.....	237	as novel therapeutic.....	738
growth suppression of human ovarian tumor xenografts		Glycoprotein mucin MUC1.....	491
in nude mice by.....	237	as target for cancer immunotherapy.....	493
EGFR.....	691	Glycosylation patterns.....	492
directed antibodies.....	703	in normal epithelial cells/aberrant breast cells.....	492
in salivary gland cancers.....	702	Gonadotropin-releasing hormone (GnRH) receptors.....	257
in thyroid carcinoma.....	702	agonists of.....	259,262
internalization of.....	693	antagonists of.....	259
mechanism of signaling of.....	692	expression of.....	261
role in mediating resistance to radiation.....	692	in regulation of tumor growth/progression.....	261
structure of.....	692	in tumors.....	257
Epigenetics.....	346,533	Gynecologic cancers.....	333
aberrations in prostate cancer.....	534	G3139 for.....	338
changes as therapeutic targets.....	542	molecular basis of apoptosis pathway in.....	335
molecular basis of.....	346	targeted therapies in.....	333
Epithelial growth factor receptors.....	271	targeting angiogenesis for.....	352
Estrogen.....	40	targeting apoptosis for.....	335
Estrogen receptor alpha.....	39	targeting cell cycle for.....	349
breast cancer cell lines as experimental models		targeting drug resistance for.....	347
to study of.....	52	targeting epigenetic modification for.....	346
chaperoning of.....	43	targeting estrogen signaling pathway for.....	350
characteristics of.....	43	targeting protein folding/degradation for.....	348
distribution/molecular heterogeneity of.....	50	targeting Ras/Raf/MAP kinase pathway for.....	340
domains of.....	46	targeting signal transduction for.....	340
effect on cell nucleus.....	44	therapies targeting apoptosis pathway for.....	338
effect on microsomes.....	45	therapies targeting ERBB axis for.....	341
effect on nucleocytoplasmic translocation.....	45	therapies targeting mTOR pathway for.....	345
effect on plasma membrane.....	44	vaccine therapy for.....	354
gene structure/expression of.....	43	Head and neck cancer.....	691
ligand-binding domain of.....	48	combination of cisplatin/cetuximab/RT in.....	698
mediated transcription.....	47	EGFR inhibitor therapies for.....	702
proteasomal degradation in mediated transcription.....	47	EGFR-targeting monoclonal antibodies in.....	691
role in ligand-independent transcription.....	47	uses of cetuximab in.....	699
role in membrane associated transcription.....	47	Hematological malignancies.....	671
role of ligand-induced transcription.....	47	chemopreventive agents for.....	675
subcellular distribution/functions of.....	43	chemotherapy agents for.....	674
Estrogen receptor ligands.....	40	deregulation of JAK-STAT pathway in.....	672
Estrogen signaling pathway.....	350	histone deacetylase inhibitors (HDACIs) for.....	674
molecular basis of.....	350	monoclonal antibodies for.....	674
Farnesyltransferase inhibitors.....	18	PPAR $\gamma$ agonist for.....	675
clinical trials of.....	19	signal transduction inhibitors for.....	676
combination with anti-cancer agents.....	19	tyrosine kinase inhibitors for.....	675
in clinical trials.....	18	<i>HER-2 (ERBB2)</i> .....	579
		in chemoresponsiveness.....	586
		genetic changes in.....	588

simultaneous amplification of.....	579	in chronic myelogenous leukemia.....	674
targeted chemotherapy role of.....	583	in hematopoietic stem cells.....	671
Human cancer.....	681	in multiple myeloma.....	674
effect of synthetic bile acids on.....	681	in mycosis fungoides.....	673
induction of apoptosis in.....	681	in Sezary syndrome.....	673
modulation of cell cycle in.....	681	in myeloproliferative disorders.....	672
Human gliomas.....	433	in T-cell acute lymphoblastic leukemia of childhood.....	673
ABC transporters.....	435	physiological role of.....	671
carboplatin for.....	435	strategies to inhibit.....	674
chemoresistance of.....	433	JAK/STAT signaling.....	108
doxorubicin for.....	435	endogenous regulators of.....	108
epidemiology of.....	433	pharmacological intervention with.....	115
histological classification of.....	433	PTP in.....	111
nitrosoureas for.....	434	role of ISGylation in.....	109
PCV for.....	435	role of protein tyrosine phosphatase (PTP) in.....	109
prognosis of.....	433	role of SOCS (suppressors of cytokine signaling) proteins in.....	108
role of ABC transporters in.....	433	role of ubiquitnylation in.....	109
temozolomide (TMZ) for.....	435	Liposomal muramyl tripeptide phosphatidylethanolamine .....	123
treatment strategies for.....	434	animal trials of.....	124
Human ribonucleotide reductase inhibitors.....	413	clinical development of.....	128
caracemide as.....	418	clinical efficacy of.....	129
cladribine/fludarabine as.....	417	formulation of.....	123
classification of.....	413	in combination with chemotherapy.....	129
cytarabine as.....	416	indication of.....	129
DMDC as.....	417	mechanisms of action of.....	126
gemcitabine as.....	416	preclinical studies of.....	124
nucleoside analogs as.....	413	safety/biological activity of.....	128
protein inactivation of.....	413	MDR transporters.....	295
R1 protein inhibitors as.....	413	effect of inflammatory response on.....	298
radical scavengers as.....	419	in acute inflammation.....	298
tezacitabine as.....	417	in models of inflammation.....	298
Human telomerase reverse transcriptase.....	155	knockout models of.....	304
post-transcriptional/post-translational modifications of.....	161	post-transcriptional regulation of.....	303
transcriptional regulation of.....	159	post-translational regulation of.....	303
Hypophysiotropic GnRH.....	257	transcriptional regulation of.....	302
Hypoxia.....	470	Metabolic pathways.....	77
Imatinib.....	645	disruption of.....	77
clinical use of.....	647	Metastasis.....	733
mechanisms of action of.....	646	basic biology of.....	745
mechanisms of resistance in CML patients using.....	645	related genes of.....	744
strategies for overcoming resistance by.....	650	strategies against.....	735
in cancer cells.....	493	Mevalonate pathway.....	15
Inflammation.....	300	consequences of disruption of.....	17
Integrins.....	89	radiation resistance with inhibitors of.....	26
as interface between cells/extracellular matrix.....	90	role in malignancy.....	16
as oncogene.....	92	Micro-environment-angiogenesis.....	470
as pharmaceutical target of anti-cancer drugs.....	97	MRP1.....	437
as tumor suppressor gene.....	92	mTOR pathway.....	345
in cancer treatment.....	89	molecular basis of.....	345
in tumor biology.....	89	Multidrug resistance (MDR).....	189,295
in tumor-induced angiogenesis.....	96	cytokines in.....	298
Invasion.....	735	gene polymorphisms of.....	304
strategies against.....	735	immunotherapy for.....	305
JAK-STAT pathway.....	671	MDR gene polymorphisms of.....	304
as therapeutic target in hematological malignancies.....	671	mechanisms/signaling transduction pathways in.....	301
in acute lymphoblastic leukemia.....	674	relationship with cytochrome P450s/acute inflammation.....	304
in acute myeloid leukemia.....	673	role of transporters in.....	295
in acute promyelocytic leukemia.....	674		
in adult T-cell leukemia/lymphoma.....	673		
in chronic lymphocytic leukemia.....	674		

Myelodysplastic syndrome (MDS) .....	553	induced senescence.....	609
AML1/RUNX1 gene in .....	553	molecular mechanisms of.....	607
cytogenetic/genetic alterations in .....	554	Oncogene-blocking therapies .....	603
implications of somatic mutations in .....	553	Osteosarcoma .....	123
molecular target therapy for .....	553,560	activating macrophages for adjuvant treatment of.....	123
Nasopharyngeal carcinoma .....	701	Ovarian cancer .....	229
EGFR antibodies in.....	701	molecular mechanism of 1,25(OH) <sub>2</sub> D <sub>3</sub> actions in .....	232
Non-nucleotidic compounds.....	80	Ovarian carcinomas.....	207
targeting PI3K pathway with .....	80	inhibition of GST-mediated drug inactivation in .....	213
Non-small cell lung cancer.....	271	mechanisms of drug resistance in.....	208
angiogenesis in .....	276	molecular targets of.....	207
angiostatin/endostatin for .....	278	novel cytotoxic agents for .....	210
bevacizumab for .....	277	pharmacokinetic approaches to overcome	
bexarotene for .....	283	resistance in.....	210
bortezomib for .....	280	reversal of MDR phenotype in .....	212
cetuximab for.....	275	target-specific drugs in.....	214
COX-2 inhibitors for.....	279	target-specific pro-apoptotic drugs in.....	218
EGFR-TKIs for.....	275	therapeutic modulation of drug resistance in .....	212
eicosanoid pathway in .....	279	therapy with platinum compounds/taxanes .....	208
erlotinib for.....	274	with acquired resistance to platinum/taxane	
farnesyltransferase inhibitors for .....	281	chemotherapy.....	207
gefitinib for.....	273	Oxazaphosphorines .....	385
lapatinib for.....	275	antitumor activity of .....	386
LY900003/aprinocarsen/ISIS 3521 for.....	282	effect of antisense oligonucleotides on.....	395
matrix metalloproteinase inhibitors for .....	279	effect of GST modulators on.....	395
mTOR apoptotic pathway in.....	284	effect of CYPs inducers on.....	394
p53/BCL-2/BAX apoptotic pathway in.....	283	effect of ALDHs modulators on.....	395
panitumumab for.....	276	effect of DNA repair modulators on.....	395
pemetrexed for .....	284	gene delivery system in .....	396
PKC/Ras/MAPK pathway in.....	281	mechanism of action of.....	386
purine/pyrimidine synthesis in.....	284	metabolism of.....	386
rapamycin for.....	284	metabolites of.....	389
retinoid receptor pathway in.....	283	pharmacogenetics of.....	392
role of extracellular matrix/matrix		pharmacokinetics of .....	391
metalloproteinases in.....	279	pharmacology of.....	386
role of proteasome in.....	280	resistance to.....	391
targeted therapies in .....	271	reversal of resistance to .....	385
thalidomide for .....	278	transport of.....	389
TNP-470 for .....	278	p53R2.....	412
trastuzumab for .....	276	role in tumorigenesis/cancer treatment .....	412
VEGF-Trap for.....	277	Pituitary GnRH receptors.....	258
ZD6474 for .....	278	as molecular targets for clinical application of GnRH	
NOTCH inhibitors .....	316	analogs.....	259
as cancer therapeutics.....	316	Positron emission tomography (PET) .....	181
NOTCH signaling.....	313	assessment of cell proliferation by .....	181
as novel cancer therapeutic target .....	313	assessment of tumor hypoxia by.....	190
effect on cancer stem cells .....	318	3'-deoxy-3'-[ <sup>18</sup> F]fluorothymidine (FLT) in.....	185-182
in immune system.....	314	[ <sup>18</sup> F]fluoro-2-deoxyglucose (FDG) in .....	182
in skin.....	315	thallium 201 ( <sup>201</sup> Tl) in .....	186
in tumorigenesis.....	315	Post-translational modification .....	15
physiological functions of.....	314	of small GTPases .....	15
Nuclear oncology .....	181	Pro-inflammatory cytokines .....	295
2-[ <sup>18</sup> F]fluoro-2-deoxyglucose (FDG) in.....	182	regulation of multidrug resistance by.....	295
spectrum of radiopharmaceuticals in .....	181	Prostate cancer .....	533
1,25(OH) <sub>2</sub> D <sub>3</sub> .....	232	adenomatous polyposis coli/β-/γ-catenin in.....	538
G2/M arrest by.....	234	androgen receptor in.....	538
induced cell cycle arrest of ovarian cancer cells.....	232	CD44 in .....	538
induction of ovarian cancer cell apoptosis by .....	236	cell cycle-related genes in.....	539
Oncogene.....	606	E-cadherin in .....	538
expression of .....	607	endothelin receptor B in.....	537
		epigenetic influence for.....	533
		estrogen receptors in.....	539

hypermethylation in.....	537	signaling by.....	107
hypomethylation in.....	537	truncated forms of.....	112
inhibitors of DNA methyltransferase for.....	543	Single photon emission computed tomography (SPECT)	
inhibitors of histone deacetylases for.....	543	.....	181
multi-gene analysis in.....	540	assessment of cell proliferation by.....	181
RASSF1A in.....	539	assessment of tumor hypoxia by.....	190
retinoic acid receptor $\beta$ in.....	539	3'-deoxy-3'-[ <sup>18</sup> F]fluorothymidine (FLT) in.....	185
reversal of drug resistance in.....	544	2-[ <sup>18</sup> F]fluoro-2-deoxyglucose (FDG) in.....	182
therapy for.....	533	thallium 201 ( <sup>201</sup> Tl) in.....	186
Protein folding/degradation.....	348	SMAD signaling.....	571
molecular basis of.....	348	downstream targets of.....	571
Protein kinases.....	623	Statins.....	22
as drug targets in cancer.....	623	in clinical trials.....	23
historical background of.....	623	Stem cell factor.....	65
Protein tyrosine phosphatases.....	519	autocrine loops of.....	69
as positive mediators of oncogenesis.....	523	Sulforaphane.....	135
as targets for cancer therapy.....	519	in apoptosis.....	135
cell growth inhibition by.....	520	intracellular targets of.....	135
expression in tumors.....	524	mediating cell cycle arrest.....	135
suppression of transformation/tumorigenicity by.....	521	signaling pathways of.....	135
Radiation.....	447	targets of.....	136
biology of.....	448	Synthesis.....	497
genomic instability in.....	450	of amino acid building blocks bearing tumor	
in tissue homeostasis/stabilization in response to		associated carbohydrate antigens.....	497
microenvironmental fluctuations.....	448	of glycosylated amino acid building blocks.....	497
<i>in vitro</i> models to.....	448	of MUC1 glycopeptide vaccine conjugates.....	504
intervention points in cancer therapy.....	447	Synthetic bile acid.....	681
non-targeted effects of.....	447	alterations in mitochondrial function by.....	684
signaling mechanisms in.....	449	as mediator of apoptosis.....	683
Ras-homologous (Rho) GTPase.....	1	cellular/biochemical effects of.....	683
as cellular targets for novel anticancer drugs.....	1	mechanism of action in apoptosis.....	684
biological activity of.....	2	modulation of cell cycle by.....	683
in cellular response to genotoxins.....	5	Targeted therapies.....	335
in drug resistance.....	5	in gynecologic cancers.....	335
inhibition of activity of.....	8	Telomerase.....	147,153
inhibition of C-terminal isoprenylation of.....	7	and POT1.....	150
pharmacological strategies to.....	7	and TRF1.....	150
regulation of modulation functions by.....	7	and TRF2.....	150
Rho proteins.....	4	anticancer strategies based on.....	165,147
in malignant transformation.....	4	functions of.....	150,155
in tumor progression.....	4	human telomerase RNA at.....	154
inhibition of.....	9	in cancers.....	163
Ribonucleotide reductase.....	409	in clinical medicine.....	164
allosteric regulation of.....	411	in meiosis.....	152
as target for cancer therapy.....	412	proteins of.....	150
catalytic mechanism of.....	409	regulation of.....	158
function of.....	409	structure of.....	148,154
multiple regulation of.....	411	telomeric structures of.....	148
structure of.....	409	Telomeric chromatin.....	152
transcriptional regulation/protein degradation		epigenetic regulation of.....	152
regulation of.....	411	Thalidomide.....	325
Ribonucleotide reductase inhibitors.....	409	actions/mechanisms of.....	325
based gene therapy.....	421	as anti-angiogenic.....	326
catalytic mechanism of.....	409	as anticancer drug.....	325
drug design of.....	409	direct inhibition of proliferation/growth of myeloma	
Signal transducers/activators of transcription (STATs)...	107	cells by.....	325
as novel targets.....	107	effect of bone marrow microenvironment.....	326
interactions of.....	112	effect on NK cells.....	328
modifications by phosphorylation.....	110	effect on T cells.....	327
regulation of activity of.....	110	effects on bone metabolism.....	328
role of PIAS (protein inhibitors of activated STATs)...	111	immunomodulatory effect of.....	326

in myeloma therapy .....	325	functional significance of isoforms of.....	251
killing of tumor cells by.....	326	in cancer .....	251
Topoisomerase II $\alpha$ (TOP2A) genes.....	579	specialization of .....	245
simultaneous amplification of.....	579	Tumor.....	70,112,260,544
Transcription factors .....	301	constitutive activation of STAT3/STAT5 in.....	114
in APR.....	301	GnRH receptors in.....	260
Transforming growth factor beta (TGF $\beta$ ).....	565	inhibition of STAT1 expression in .....	112
adverse effects of inhibition of .....	573	markers for .....	544
anti-TGF $\beta$ antibodies to target .....	570	mutations of c-Kit in.....	70
based antisense oligonucleotides/DNAzymes .....	570	type II GnRH receptors in .....	264
context-dependent action of .....	571	Tumor ecosystem.....	737
role in therapeutic drug design .....	567	targeting of.....	737
signaling pathway of.....	565	Tumor-stroma interactions .....	472
small molecules inhibitors of.....	571	Tumor-vaccination.....	493
soluble receptors of.....	569	carbohydrates in .....	493
targeting activation of.....	568	synthetic peptides in .....	493
targeting with naturally-occurring binding proteins ..	569	Vaccine therapy.....	354
tumor biology of.....	567	molecular basis of.....	354
Transforming growth factor beta(TGF $\beta$ ) inhibitors.....	568	Vitamin D .....	229
for cancer therapy.....	573	as medicine for human diseases .....	229
therapeutic approaches with .....	568	Vitamin D receptor .....	229
Trastuzumab.....	465	as drug target for ovarian cancer treatment .....	229
cardiotoxicity by .....	466	as ligand-regulated transcription factor .....	230
combine with paclitaxel .....	466	in ovarian cancer.....	231
Tropomyosin.....	245	insufficiency of .....	231
as target for chemotherapy.....	245	NR1I1 as .....	230
composition of actin filaments of .....	245		